CAS: 1608125-21-8; (S)-N-(1-(7-Fluoro-2-(Pyridin-2-yl)Quinolin-3-yl)Ethyl)-9H-Purin-6-Amine

上下游产品

(S)-1-(7-Fluoro-2-(Pyridin-2-yl)Quinolin-3-yl)Ethanamine 1464832-50-5

📜2-氯-7-氟喹啉-3-甲醛置于manganese(Iv) Oxide,四(三苯基膦)钯,偶氮二甲酸二异丙酯,(+)-Diisopinocampheylboron Chloride,N,N-二异丙基乙胺,三苯基膦,肼体系中,用 四氢呋喃,1,4-二氧六环,乙醇,甲苯,正丁醇 用作溶剂,化学反应 1.75H,反应生成(Alphas)-7-氟-Alpha-甲基-N-9H-嘌呤-6-基-2-(2-吡啶基)-3-喹啉甲胺
参考文献: Hydrate,Crystalline Hydrate And Crystalline Anhydrate Forms Of N-((1S)-1-(7-Fluoro-2-(2-Pyridinyl)-3-Quinolinyl)Ethyl)-9H-Purin-6-Amine,Pharmaceutical Compositions Containing Them And Methods For Treating Cancer.[fr] Formes Hydratées,Cristallines Hydratées Et Cristallines Anhydres De La N-((1S)-1-(7-Fluoro-2-(2-Pyridinyl)-3-Quinolinyl)éthyl)-9H-Purine-6-Amine,Compositions Pharmaceutiques En Contenant Et Méthodes De Traitement Du Cancer
标题: Hydrate,Crystalline Hydrate And Crystalline Anhydrate Forms Of N-((1S)-1-(7-Fluoro-2-(2-Pyridinyl)-3-Quinolinyl)Ethyl)-9H-Purin-6-Amine,Pharmaceutical Compositions Containing Them And Methods For Treating Cancer.[fr] Formes Hydratées,Cristallines Hydratées Et Cristallines Anhydres De La N-((1S)-1-(7-Fluoro-2-(2-Pyridinyl)-3-Quinolinyl)éthyl)-9H-Purine-6-Amine,Compositions Pharmaceutiques En Contenant Et Méthodes De Traitement Du Cancer
摘要:本文提供了n-((1S)-1-(7-氟-2-(2-吡啶基)-3-喹啉基)乙基)-9H-嘌呤-6-胺的新颖水合物和无水物形式.本文还提供了含有这些形式的药物组合物,并提供了使用这些组合物治疗癌症的方法.

专利信息

专利号:US-2025289827-A1
优先权日:2022-12-02
标 题:Morphic forms of a mutant braf degrader and methods of manufacture thereof
发明人：YU ROBERT T; HE MINSHENG; SCHNADERBECK MATTHEW J; KREGER BRIDGET; POLLOCK ROY MACFARLANE; JIANG SIYI; LI MEIQI; CHEN BOLU; LU JIANNAN
权利人:C4 THERAPEUTICS INC
摘要:Advantageous isolated morphic forms of (3R)-3-[6-[2-cyano-3-[[ethyl(methyl)sulfamoyl]amino]-6-fluorophenoxy]-4-oxoquinazolin-3-yl]-8-[2-[1-[3-(2,4-dioxo-1,3-diazinan-1-yl)-5-fluoro-1-methylindazol-6-yl]-4-hydroxypiperidin-4-yl]acetyl]-1-oxa-8-azaspiro[4.5]decane (Compound 1), which is a mutant BRAF degrader, and methods to prepare Compound 1 morphic forms for therapeutic applications are provided in the invention. The invention also provides improved methods for the synthesis of Compound 1, new pharmaceutical compositions comprising Compound 1, and new uses of Compound 1.

专利号:US-2017107577-A1
优先权日:2014-03-11
标题:Determining Cancer Aggressiveness, Prognosis and Responsiveness to Treatment
发明人：AL-EJEH FARES
权利人:THE COUNCIL OF THE QUEENSLAND INST OF MEDICAL RES
摘要:The invention provides methods of determining the aggressiveness, prognosis and response to therapy for particular cancers, which include comparing the expression levels of one or a plurality of differentially expressed genes from one or more 5 functional metagenes, including a Carbohydrate/Lipid Metabolism metagene, a Cell Signalling metagene, a Cellular Development metagene, a Cellular Growth metagene, a Chromosome Segregation metagene, a DNA Replication/Recombination metagene, an Immune system metagene, a Metabolic Disease metagene, a Nucleic Acid Metabolism metagene, a Post-Translational Modification metagene, a Protein 10 Synthesis/Modification metagene and a Multiple Networks metagene. The method disclosed herein may be particularly suitable as a companion diagnostic for cancer therapies.

专利号:US-2022411407-A1
优先权日:2019-11-15
标题:Aryl aminopyrimidines as dual mertk and tyro3 inhibitors and methods thereof
发明人：WANG XIAODONG; ZHOU YUBAI; DING RANSHENG; KONG DEYU; FRYE STEPHEN
权利人:UNIV NORTH CAROLINA CHAPEL HILL
摘要:Aminopyrimidine containing compounds that inhibit both Mer tyrosine kinase (MerTK) activity and Tyro3 kinase activity are disclosed herein. Additionally disclosed are methods of synthesis and use of the aminopyrimidine containing compounds as anti-cancer agents, immunostimulatory and immunomodulatory agents, anti-platelet agents, anti-infective agents, and as adjunctive agents.

专利号:WO-2023144235-A1
优先权日:2022-01-27
标 题 :Methods for monitoring and treating warburg effect in patients with pi3k-related disorders
发明人：CANAUD GUILLAUME; LADRAA SOPHIA
权利人:INST NAT SANTE RECH MED; ASSIST PUBLIQUE HOPITAUX PARIS APHP; CENTRE NAT RECH SCIENT; UNIV PARIS CITE
摘要:Using a unique tool of PROS, they demonstrate that PIK3CA mutation leads to GLUT4 membrane accumulation with a negative feedback loop on insulin secretion, a burst of liver IGFBP1 synthesis with IGF1 sequestration and low circulating levels. They further show that AKT2 drives a large part of the phenotype. In addition, they demonstrate for the first time that a single PIK3CA mutation induces metabolic reprogramming with the Warburg effect and protein and lipid synthesis—hallmarks of cancer cells—in vitro, in vivo and in patients. They finally show that alpelisib, an approved PIK3CA inhibitor in oncology, is efficient at preventing and improving PIK3CA-adipose tissue overgrowth and reversing metabolomic anomalies in both animal models and patients. Accordingly, the present invention relates to an in vitro method for monitoring the efficiency of a PI3K inhibitor treatment in a subject in need thereof comprising the step of determining the level of at least one metabolite selected in the group consisting of cis-aconitate, succinic acid, 5-methylcytosine, acetyl-carnitine, acetyl-lysine, argininosuccinate, betaine, butyric acid, carnitine, creatine, glucose, glycine, hexanoyl-carnitine, L-fucose, lactate, L-dihydroorotic acid, linolenic acid, nicotinamide N-oxide, palmitoyl-carnitine, panthotenate, pyruvate, quinolinic acid, tryptophan, urate, in a biological sample obtained from the subject.